InflaRx (IFRX) shares were down more than 18% in premarket activity Friday after the company said overnight it priced an offering of 8.25 million ordinary shares at $2 apiece.
The offering includes pre-funded warrants to purchase up to 6.75 million of the company's ordinary shares, the company said late Thursday, adding that the net proceeds will primarily fund the clinical development of pipeline candidates, including vilobelimab and INF904.
InflaRx granted underwriters a 30-day option to purchase up to 2.25 million additional shares. It is selling all the securities in the offering, which is expected to close on Feb. 18.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.